Aptose Biosciences Inc. (APTO) Total Debt to Capital

Aptose Biosciences Inc. - graphic logo of issuer APTO

Aptose Biosciences Inc. (APTO) is developing a comprehensive system for targeted impact on malignant hematopoiesis, creating vital treatments for myeloid leukemias. As the company is currently in the clinical trial stage, it generates no revenue, and its financial stability relies on the strict optimization of development costs. This chart of the stock price reflects a total debt-to-equity ratio of 0.00, which is critical given the high demand for new kinase inhibitors.

Aptose Biosciences Inc (APTO): Debt to Equity Ratio from 07/04/2022 to 04/13/2025

Metric breakdowns and analytics for Aptose Biosciences (APTO)

- share price and consensus valuation forecast:
Stock Price Aptose Biosciences Inc|APTO - Consensus Target
- market capitalization details:
Market Capitalization Aptose Biosciences|APTO - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Aptose Biosciences|APTO - Accounting Capitalization|Market Capitalization to Book Value Ratio aptose.com|APTO - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Aptose Biosciences Inc.|APTO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Aptose Biosciences Inc|APTO - Aggregate Debt Obligations|Debt to Book Value Aptose Biosciences|APTO - Company Long-Term Loans and Borrowings|Company Short-Term Debts Aptose Biosciences|Quick Liquidity aptose.com
- net income and valuation ratios data:
APTO - Company Net Income
Fundamental company valuation:Aptose Biosciences Inc.
Finished products of Aptose Biosciences Inc

This ratio is calculated as the sum of all debt obligations divided by the amount of equity, which allows for an assessment of the degree of financial leverage and the overall stability of the balance sheet structure. For Aptose Biosciences Inc. (APTO), which invests in the development of targeted leukemia drugs, a low debt-to-equity ratio is critically important to ensure uninterrupted funding for long-term small molecule clinical trials.

Competitor analysis for Aptose Biosciences Inc.

TGTX (TG Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Arcellx Inc (ACLX)|Total Debt to Capital IRON|Total Debt to Capital Syndax Corp (SNDX)|Debt to Equity Kura Oncology, Inc. KURA|ADCT: Debt to Equity Ratio|Foghorn - Total Debt to Capital|Vor Biopharma, Inc. (VOR) - Total Debt to Equity Ratio|NKTX: Total Debt to Capital|Debt to Capital Coeptis Therapeutics, Inc. (COEP)|Debt to Equity Actinium Pharmaceuticals|ESLA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CASI (CASI Pharmaceuticals)|MRKR (markertherapeutics.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital INAB (IN8bio, Inc)|Eterna Therapeutics, Inc. - Debt to Equity|GTBP - Debt to Equity|BPTH: Debt to Equity|MEI Pharma (MEIP) - Debt to Equity|Debt to Capital Vincerx Pharma (VINC)